Radioactive Iodine Ablation Can Reduce the Structural Recurrence Rate of Intermediate-Risk Papillary Thyroid Microcarcinoma: A Meta-Analysis

Table 1

Cohort characteristics of included studies.

Study	Country		Mean age	Female/male	Mean tumor size (mm)	Histology	MF (%)	METE (%)	LNM (%)	Treat with RAI	RAI dose (mCi)	F/U year
Xue et al. [16]	China	137	NA	101/36	NA	PTMC	75.2	92.0	92.0	94	30-150	6.8
Kim and Kim [17]	Korea	704	47.0	631/73	6.0	PTMC	32.0	46.0	24.0	578	100	5.3
Creach et al. [18]	America	407	45.0	321/86	7.0	PTMC	46.2	NA	NA	NA	100	5.3
Neuhold et al. [19]	Austria	759	53.0	586/173	3.8	PTMC	31.2	NA	2.7	173	30	7.3
Moon et al. [20]	Korea	288	46.6	262/26	6.2	PTMC	20.5	30.9	33.7	114	30	6.0
Durante et al. [21]	Italy	312	47.5	277/35	5.0	PTMC	NA	0	0	137	73	6.7
Kim et al. [22]	Korea	307	46.0	275/32	8.0	PTMC	31.9	37.8	45.3	163	75-150	5.4
Chow et al. [23]	China	203	46.8	176/27	7.0	PTMC	31.0	20.7	24.6	137	80	8.4

PTMC: papillary thyroid microcarcinoma; LR: low risk; IR: intermediate risk; MF: multifocality; METE: microscope extrathyroidal extension; LNM: lymph node metastasis; RAI: radioiodine ablation, F/U: follow-up; NA: not available.